Curocell, an immunotherapy developer, is drawing investors’ attention as the company commercializes a domestic CAR-T (chimeric antibody receptor-T cell) therapy and makes a debut on the stock market in the latter half-year.According to the Korea Stock Exchange (KRX), Curocell requested a preliminary
Celltrion said it has signed a joint research and development agreement with Basgen Bio, a big data company, to strengthen its bio data analysis capabilities.Under the contract, the two companies will form a joint research committee and conduct 10 related joint research and development projects over
People Bio’s plan to supply the kit to diagnose Alzheimer’s to Singapore has hit a snag.The company said in a public filing on Thursday that its contract with Singapore’s in vitro diagnosis supplier All Eights to supply Alzheimer’s diagnosis kits has been canceled by mutual consent. The contract was
SK Bioscience on Thursday unveiled the new "SKBS 3.0" growth strategy, prioritizing the expansion of cell and gene therapy (CGT) and boosting sales of existing vaccines.In a public filing, the company unveiled its funding plan to invest about 2.4 trillion won ($1.7 billion) over the next five years
S.Biomedics, a cell therapy developer, said Wednesday that the competition rate was 994.8 to 1 in initial public offering subscriptions conducted on Monday and Tuesday.A total of 85,531 subscriptions were received for S.Biomedics’ public offering to general investors. The deposits were estimated at
Korea Biotechnology Industry Organization (Korea BIO) and the U.S. Biotechnology Innovation Organization (BIO) signed a memorandum of understanding (MOU) to promote the bioeconomy of both countries on Tuesday (local time) in Washington, DC, on the sideline of President Yoon Suk Yeol’s state visit.Th
Celltrion said it has completed a marketing authorization application for CT-P39, a biosimilar referencing Xolair (ingredient: omalizumab), to the European Medicines Agency (EMA).Xolair, the original drug, is an antibody biologic developed by Genentech and Novartis for the treatment of allergic asth
Samsung Bioepis said SB15, a biosimilar candidate referencing Eylea (ingredient: aflibercept), demonstrated similar efficacy, safety, immunogenicity, and pharmacokinetics (PK) to the original drug in a phase 3 clinical trial. During the 2023 Annual Meeting of the Association for Research in Vision a
Biotherapeutics has obtained approval for its investigational new drug (IND) plan to conduct the phase 1.2 clinical trial of the fourth-generation EGFR-mutant non-small cell lung cancer targeted agent, BBT-207, from the U.S. Food and Drug Administration. Bridge Bio said in a public filing on Monday
Lotte Biologics said it has made an equity investment in Pinot Bio, a Korean developer of antibody-drug conjugate (ADC) platforms.Through this equity investment, the two companies plan to form a strategic business partnership and strengthen ADC platform technology development and production synergie
HLB has entered the finishing stage of splitting off its ship business sector.The company said Thursday that it has completed the procedure for its shareholders exercising claims for stock purchase to split off HLB ENG, its ship business unit.“The buyback request procedure ended without any accident
A team of researchers at KAIST said on Thursday that they developed a treatment for second-generation T cell receptor-engineered T cells (TCR-T) that overcome the tumor microenvironment for solid cancers where the immune system is suppressed.First-generation chimeric antigen receptor T cells, abbrev
Therapex said it has presented the preclinical trial results of TRX-221, its fourth-generation non-small cell lung cancer (NSCLC) drug candidate, at the American Association for Cancer Research (AACR) 2023 Conference in Orlando, Florida, the U.S., on Tuesday.TRX-221 is a broad-spectrum fourth-genera
A recent study conducted by a joint research team from the Institute for Basic Science (IBS), KAIST, and Severance Hospital has successfully visualized reactive astrocytes during neuronal hypometabolism, presenting a way for early diagnosis of Alzheimer's disease.Alzheimer's disease is typically ass
GI Cell has won approval for phase 1 IND (investigational new drug) for allogeneic NK cell therapy. The company will also push for its combined administration with immunotherapy candidate substance of its affiliate, GI Innovation.GI Cell said Monday that it has obtained approval for the phase 1 clin
NKGen Biotech, the U.S. subsidiary of NKMAX, a Korean natural killer-cell-based immunotherapy company, has moved closer to being listed on the New York Stock Exchange.NKGen said last Friday (local time) that it has signed a merger contract with Graf Acquisition Corp. IV, a special purpose acquisitio
Celltrion Healthcare has launched its Avastin biosimilar Vegzelma (ingredient: bevacizumab) to treat metastatic colorectal cancer and breast cancer in the U.S., starting the direct sales of its treatments in the country.Following its approval from the U.S. Food and Drug Administration (FDA) in Septe
Researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) have developed a novel nanopore sensor that efficiently screens protein-drug interactions, enabling faster drug discovery while minimizing associated costs.Candidate discovery analyzes the binding between target dise
Samsung Biologics and Samsung C&T said they plan to invest in Araris Biotech AG, a Swiss-based biopharmaceutical company that develops antibody-drug conjugate (ADC) therapies and owns proprietary ADC linker technology.The investment was made via Samsung Life Science Fund – created jointly between Sa
Nature Cell said Tuesday that it could not accept the Ministry of Food and Safety’s decision to reject its application for Joint Stem, stem cell treatment for degenerative arthritis.“As the developer of this product, we have submitted sufficient data about the clinical significance that fit the appl